Kiniksa Pharmaceuticals International (KNSA) Expected to Release Earnings on Tuesday

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is expected to announce its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect Kiniksa Pharmaceuticals International to announce earnings of $0.30 per share and revenue of $226.4880 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:30 AM ET.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. During the same period in the previous year, the firm posted $0.11 EPS. Kiniksa Pharmaceuticals International’s revenue was up 55.5% on a year-over-year basis. On average, analysts expect Kiniksa Pharmaceuticals International to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Kiniksa Pharmaceuticals International Stock Down 2.1%

Shares of Kiniksa Pharmaceuticals International stock opened at $62.58 on Tuesday. Kiniksa Pharmaceuticals International has a fifty-two week low of $26.27 and a fifty-two week high of $67.53. The firm has a market cap of $4.81 billion, a PE ratio of 69.53 and a beta of 0.07. The business’s fifty day moving average is $56.51 and its two-hundred day moving average is $49.42.

Analyst Upgrades and Downgrades

Several research firms have commented on KNSA. Citigroup lifted their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 23rd. Finally, Canaccord Genuity Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $65.14.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, Director Barry D. Quart sold 13,099 shares of the company’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total value of $656,259.90. Following the completion of the transaction, the director directly owned 12,546 shares in the company, valued at approximately $628,554.60. This represents a 51.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of the firm’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $51.86, for a total transaction of $25,082,296.44. Following the sale, the chief executive officer directly owned 431,904 shares of the company’s stock, valued at approximately $22,398,541.44. The trade was a 52.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 628,427 shares of company stock valued at $32,833,228. Corporate insiders own 51.98% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Empowered Funds LLC acquired a new stake in Kiniksa Pharmaceuticals International in the fourth quarter valued at $51,000. XTX Topco Ltd acquired a new position in Kiniksa Pharmaceuticals International during the 4th quarter worth $291,000. Financiere des Professionnels Fonds d investissement inc. bought a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth about $222,000. Franklin Resources Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at about $204,000. Finally, PharVision Advisers LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at about $261,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.